As the club’s official pain relief partner, Maxigesic® will also be the presenting partner for a ‘Big Hit of the Week’ video feature as well as the weekly recovery report.
“We’ve come off a watershed season in 2023 but 2024 is even bigger for us as we field an unprecedented five teams across various competitions,” said One New Zealand Warriors general manager commercial and consumer business Glenn Critchley.
“So partnering with an innovative brand leader like Maxigesic® is critical. We’re thrilled to have them on board.”
Developed and marketed by Takapuna-based AFT Pharmaceuticals, the patented Maxigesic® combination of Paracetamol and Ibuprofen is now sold in more than 60 countries worldwide.
“We’re very excited to have Maxigesic® partner with the One New Zealand Warriors family and form a perfect combination for the next two seasons,” said Hartley Atkinson, chief executive of AFT Pharmaceuticals and inventor of Maxigesic®.
“We feel a real affinity with the One New Zealand Warriors and their journey. Having initially developed and launched Maxigesic® at home in New Zealand, we’ve taken on the Australian market and established Maxigesic® as the number one selling Paracetamol/Ibuprofen combination* on the other side of the Tasman, so we’re fully supportive of the One New Zealand Warriors achieving their own historic milestone of winning a first NRL title.
“By bringing Maxigesic® and the One New Zealand Warriors together, we’re confident that we Kiwis are going to fly, both at home and away, in the 2024 season.”
Maxigesic® was developed as a smarter alternative that provides faster and more effective pain relief than other analgesics, particularly those containing opioids, and is clinically proven to provide 78 per cent more effective pain relief than Paracetamol alone and 36 per cent more effective pain relief than Ibuprofen alone¹.
Leave a Reply